---
analyst: amantonio
---

Clinical trials of the safety of Recombivax [were conducted](https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm110114.pdf) on 147 infants and children, as well as 1,252 adults, and lasted 5 days after each dose. There was no control group.
Clinical trials of the safety of Engerix-B [lasted](https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf) 4 days after each dose. There was no control group.
